The precise mechanism by which KESIMPTA exerts its therapeutic effects in multiple sclerosis is unknown but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, KESIMPTA results in antibody-dependent cellular cytolysis and complement-mediated lysis.1 Learn more about the mechanism of action
CDP, confirmed disability progression; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; HCP, health care professional; IgG, immunoglobulin G; MS, multiple sclerosis.
*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA and is intended to give patients a chance to see if KESIMPTA may be right for them.
†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.